相似文献
1
Myocardial ischemia-reperfusion injury: a neglected therapeutic target.
J Clin Invest. 2013 Jan;123(1):92-100. doi: 10.1172/JCI62874. Epub 2013 Jan 2.
2
Myocardial reperfusion injury: looking beyond primary PCI.
Eur Heart J. 2013 Jun;34(23):1714-22. doi: 10.1093/eurheartj/eht090. Epub 2013 Mar 27.
3
Reducing myocardial infarct size: challenges and future opportunities.
Heart. 2016 Mar;102(5):341-8. doi: 10.1136/heartjnl-2015-307855. Epub 2015 Dec 16.
4
Mechanistic Role of mPTP in Ischemia-Reperfusion Injury.
Adv Exp Med Biol. 2017;982:169-189. doi: 10.1007/978-3-319-55330-6_9.
5
6
Signalling pathways in ischaemic postconditioning.
Thromb Haemost. 2009 Apr;101(4):626-34.
7
High-dose Humanin analogue applied during ischemia exerts cardioprotection against ischemia/reperfusion injury by reducing mitochondrial dysfunction.
Cardiovasc Ther. 2017 Oct;35(5). doi: 10.1111/1755-5922.12289.
8
Shining the spotlight on cardioprotection: beyond the cardiomyocyte.
Cardiovasc Res. 2019 Jun 1;115(7):1115-1116. doi: 10.1093/cvr/cvz072.
9
Inhibition of dynamin-related protein 1 protects against myocardial ischemia-reperfusion injury in diabetic mice.
Cardiovasc Diabetol. 2017 Feb 7;16(1):19. doi: 10.1186/s12933-017-0501-2.
10
Pharmacological prevention of reperfusion injury in acute myocardial infarction. A potential role for adenosine as a therapeutic agent.
Am J Cardiovasc Drugs. 2004;4(3):159-67. doi: 10.2165/00129784-200404030-00003.
引用本文的文献
1
Sevoflurane Suppresses Cardiomyocyte Pyroptosis in Myocardial Ischemia via NLRP3 Inflammasome Signaling.
Anal Cell Pathol (Amst). 2025 Aug 24;2025:7119597. doi: 10.1155/ancp/7119597. eCollection 2025.
2
Transcription factor ETV1 promotes angiogenesis after myocardial infarction via activation of the VEGFA/VEGFR2/eNOS pathway.
Front Cardiovasc Med. 2025 Aug 15;12:1633438. doi: 10.3389/fcvm.2025.1633438. eCollection 2025.
3
MAFF mitigates oxidative stress and pyroptosis in cardiopulmonary bypass-induced myocardium injury.
Front Physiol. 2025 Jul 31;16:1516167. doi: 10.3389/fphys.2025.1516167. eCollection 2025.
4
Clinical study of Yiqi Liangxue Shengji prescription for improving cardiac function after myocardial ischemia reperfusion injury in patients with acute myocardial infarction: a randomized, double-blind, placebo-controlled trial.
J Tradit Chin Med. 2025 Aug;45(4):836-844. doi: 10.19852/j.cnki.jtcm.2025.04.012.
5
Macrophage Polarization in Myocardial Ischemia‒Reperfusion Injury: Pathophysiology and Therapeutic Targets.
Drug Des Devel Ther. 2025 Jul 31;19:6519-6541. doi: 10.2147/DDDT.S516001. eCollection 2025.
6
Gypensapogenin I alleviates PANoptosis, ferroptosis, and oxidative stress in myocardial ischemic-reperfusion injury by targeting the NOX2/AMPK pathway.
Front Cell Dev Biol. 2025 Jul 22;13:1623846. doi: 10.3389/fcell.2025.1623846. eCollection 2025.
7
Cardioprotective Effects of Bosentan in Rats Subjected to Lung Ischemia-Reperfusion Injury.
Medicina (Kaunas). 2025 Jul 18;61(7):1298. doi: 10.3390/medicina61071298.
8
Extract of G. Don, a Medicinal Plant, Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Platelet Activation.
Curr Issues Mol Biol. 2025 Jul 1;47(7):503. doi: 10.3390/cimb47070503.
9
Single-atom Pt-doped ceria nanozymes mitigate myocardial ischemia reperfusion injury via cardiomyocyte-targeted uptake and suppression of reactive oxygen species.
Bioact Mater. 2025 Jul 20;53:366-385. doi: 10.1016/j.bioactmat.2025.07.019. eCollection 2025 Nov.
10
Unveiling the Cardioprotective Potential of Hydroxytyrosol: Insights from an Acute Myocardial Infarction Model.
Antioxidants (Basel). 2025 Jun 28;14(7):803. doi: 10.3390/antiox14070803.
本文引用的文献
1
Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia.
Circ Cardiovasc Interv. 2012 Apr;5(2):288-95. doi: 10.1161/CIRCINTERVENTIONS.112.968388. Epub 2012 Apr 10.
2
Postconditioning during coronary angioplasty in acute myocardial infarction: the POST-AMI trial.
Int J Cardiol. 2012 Dec 15;162(1):33-8. doi: 10.1016/j.ijcard.2012.03.136. Epub 2012 Apr 9.
3
Out-of-hospital administration of intravenous glucose-insulin-potassium in patients with suspected acute coronary syndromes: the IMMEDIATE randomized controlled trial.
JAMA. 2012 May 9;307(18):1925-33. doi: 10.1001/jama.2012.426. Epub 2012 Mar 27.
4
Early statin treatment prior to primary PCI for acute myocardial infarction: REPERATOR, a randomized placebo-controlled pilot trial.
Catheter Cardiovasc Interv. 2012 Nov 1;80(5):756-65. doi: 10.1002/ccd.23449. Epub 2012 Mar 14.
5
Effects of atorvastatin pretreatment on infarct size in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Am Heart J. 2011 Dec;162(6):1026-33. doi: 10.1016/j.ahj.2011.08.011.
6
STAT5 activation and cardioprotection by remote ischemic preconditioning in humans: short communication.
Circ Res. 2012 Jan 6;110(1):111-5. doi: 10.1161/CIRCRESAHA.111.259556. Epub 2011 Nov 23.
7
Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction.
Eur Heart J. 2012 Jun;33(12):1491-9. doi: 10.1093/eurheartj/ehr309. Epub 2011 Sep 14.
8
Reduction of infarct size by ischaemic post-conditioning in humans: fact or fiction?
Eur Heart J. 2012 Jan;33(1):13-5. doi: 10.1093/eurheartj/ehr341. Epub 2011 Sep 11.
9
Effect of erythropoietin as an adjunct to primary percutaneous coronary intervention: a randomised controlled clinical trial.
Heart. 2011 Oct;97(19):1560-5. doi: 10.1136/hrt.2011.223867.
10
New horizons in cardioprotection: recommendations from the 2010 National Heart, Lung, and Blood Institute Workshop.
Circulation. 2011 Sep 6;124(10):1172-9. doi: 10.1161/CIRCULATIONAHA.111.032698.
Zotero 插件